Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Decreases By 96.2%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 582 shares, a decline of 96.2% from the August 15th total of 15,394 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 61,763 shares, the short-interest ratio is presently 0.0 days.

Revelation Biosciences Trading Down 1.5%

NASDAQ REVB traded down $0.01 during midday trading on Thursday, hitting $0.99. The company had a trading volume of 4,923 shares, compared to its average volume of 40,507. The company has a market capitalization of $3.96 million, a PE ratio of -0.08 and a beta of -0.14. The firm has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.11. Revelation Biosciences has a twelve month low of $0.88 and a twelve month high of $8.40.

Revelation Biosciences (NASDAQ:REVB) last released its earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.01. On average, equities analysts anticipate that Revelation Biosciences will post -5.18 EPS for the current year.

Institutional Investors Weigh In On Revelation Biosciences

A number of large investors have recently bought and sold shares of REVB. Armistice Capital LLC increased its holdings in Revelation Biosciences by 442.8% in the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after buying an additional 354,272 shares during the period. Sabby Management LLC lifted its holdings in shares of Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after acquiring an additional 398,651 shares during the period. Finally, Geode Capital Management LLC bought a new stake in shares of Revelation Biosciences during the 4th quarter worth approximately $27,000. 12.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, August 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.